DOCSLIB.ORG

Aprotinin Inhibits SARS-Cov-2 Replication

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aprotinin Inhibits SARS-Cov-2 Replication cells Article Aprotinin Inhibits SARS-CoV-2 Replication Denisa Bojkova 1, Marco Bechtel 1, Katie-May McLaughlin 2, Jake E. McGreig 2 , Kevin Klann 3 , Carla Bellinghausen 4 , Gernot Rohde 4 , Danny Jonigk 5,6, Peter Braubach 5,6, Sandra Ciesek 1,7,8 , Christian Münch 3,9,10 , Mark N. Wass 2,* , Martin Michaelis 2,* and Jindrich Cinatl, Jr. 1,* 1 Institute for Medical Virology, University Hospital, Goethe University, 60596 Frankfurt am Main, Germany; [email protected] (D.B.); [email protected] (M.B.); [email protected] (S.C.) 2 School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK; [email protected] (K.-M.M.); [email protected] (J.E.M.) 3 Faculty of Medicine, Institute of Biochemistry II, Goethe University, 60590 Frankfurt am Main, Germany; [email protected] (K.K.); [email protected] (C.M.) 4 Department of Respiratory Medicine and Allergology, University Hospital, Goethe University, 60590 Frankfurt am Main, Germany; [email protected] (C.B.); [email protected] (G.R.) 5 Institute of Pathology, Hannover Medical School (MHH), 30625 Hannover, Germany; [email protected] (D.J.); [email protected] (P.B.) 6 Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), The German Center for Lung Research (Deutsches Zentrum für Lungenforschung, DZL), Hannover Medical School (MHH), 30625 Hannover, Germany 7 German Center for Infection Research, DZIF, External Partner Site, 60596 Frankfurt am Main, Germany 8 Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine und Pharmacology, 60596 Frankfurt am Main, Germany 9 Frankfurt Cancer Institute, Goethe University, 60596 Frankfurt am Main, Germany 10 Cardio-Pulmonary Institute, Goethe University, 60590 Frankfurt am Main, Germany * Correspondence: [email protected] (M.N.W); [email protected] (M.M.); [email protected] (J.C.J.) Received: 28 June 2020; Accepted: 28 October 2020; Published: 30 October 2020 Abstract: Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S) protein by cellular proteases. Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations. An analysis of proteomics and translatome data indicated that SARS-CoV-2 replication is associated with a downregulation of host cell protease inhibitors. Hence, aprotinin may compensate for downregulated host cell proteases during later virus replication cycles. Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air–liquid interface cultures) and against four virus isolates. In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity. An approved aprotinin aerosol may have potential for the early local control of SARS-CoV-2 replication and the prevention of COVID-19 progression to a severe, systemic disease. Keywords: severe acute respiratory syndrome coronavirus; severe acute respiratory syndrome coronavirus 2; 2019-nCoV; COVID-19; antiviral; drug discovery; aprotinin Cells 2020, 9, 2377; doi:10.3390/cells9112377 www.mdpi.com/journal/cells Cells 2020, 9, 2377 2 of 13 1. Introduction Severe acute respiratory syndrome virus 2 (SARS-CoV-2), a novel betacoronavirus, causes a respiratory disease and pneumonia called coronavirus disease 19 (COVID-19) and is the cause of a current pandemic responsible for millions of cases and hundreds of thousands of deaths [1–7]. Drugs for the treatment of COVID-19 are urgently needed. Cell entry of coronaviruses is mediated by the interaction of the viral spike (S) protein with their host cell receptors, which differ between different coronaviruses [8]. For example, Middle East respiratory syndrome coronavirus (MERS-CoV) uses dipeptidyl peptidase 4 (DPP4) as a cellular receptor [8]. Host cell entry of SARS-CoV-2 and of the closely related severe acute respiratory syndrome virus (SARS-CoV) is mediated by angiotensin-converting enzyme 2 (ACE2) [8–10]. S binding to ACE2 depends on S cleavage at three sites (S1, S2, and S2’) by host cell proteases, typically by the transmembrane serine protease 2 (TMPRSS2), and can be inhibited by serine protease inhibitors [9,10]. Camostat was the first serine protease inhibitor that was shown to inhibit TMPRSS2 [9]. Subsequently, additional TMPRSS2 inhibitors, including nafamostat and Arbidol derivatives, were demonstrated to interfere with SARS-CoV-2 internalization into host cells [11–13]. Aprotinin is a serine protease inhibitor, which has previously been shown to inhibit TMPRSS2 and has been suggested as a treatment option for influenza viruses and coronaviruses [14,15]. Herein, we investigated the effects of aprotinin against SARS-CoV-2. 2. Materials and Methods 2.1. Drugs SERPINA1/alpha-1 antitrypsin (Prolastin) was obtained from Grifols (Barcelona, Spain). Aprotinin was purchased from Sigma-Aldrich (Darmstadt, Germany)). 2.2. Cell Culture The Caco2 cell line was obtained from DSMZ (Braunschweig, Germany), and Calu-3 from ATCC (Manassas, VA, US). The cells were grown at 37 ◦C in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 100 IU/mL of penicillin, and 100 µg/mL of streptomycin. All culture reagents were purchased from Sigma-Aldrich. Cells were regularly authenticated by short tandem repeat (STR) analysis and tested for mycoplasma contamination. Lung tissue for the isolation of primary epithelial cells was provided by the Hannover Medical School, Institute of Pathology (Hannover, Germany). The use of tissue was approved by the ethics committee of the Hannover Medical School (MHH, Hannover, Germany, number 2701–2015) and was in compliance with The Code of Ethics of the World Medical Association. Primary bronchial epithelial cells were isolated from the lung explant tissue of a patient with lung emphysema as described previously [16]. All patients or their next of kin gave written informed consent for the use of their lung tissue for research. Basal cells were expanded in Keratinocyte-SFM medium supplemented with bovine pituitary extract (25 µg/mL), human recombinant epidermal growth factor (0.2 ng/mL, all from Gibco, Schwerte, Germany), isoproterenol (1 nM, Sigma), Antibiotic/Antimycotic Solution (Sigma-Aldrich), and MycoZap Plus PR (Lonza, Cologne, Germany) and cryopreserved until further use. For differentiation, the cells were thawed and passaged once in PneumaCult-Ex Medium (StemCell Technologies, Cologne, Germany) and then seeded on transwell inserts (12-well plate, Sarstedt, Nümbrecht, Germany) at 4 104 cells/insert. Once the cell layers reached confluency, the medium on × the apical side of the transwell was removed, and medium in the basal chamber was replaced with PneumaCult ALI Maintenance Medium (StemCell Technologies), including Antibiotic/Antimycotic Solution (Sigma-Aldrich) and MycoZap Plus PR (Lonza). During a period of four weeks, the medium was changed and the cell layers were washed with PBS every other day. Criteria for successful differentiation were the development of ciliated cells and ciliary movement, an increase in transepithelial electric resistance indicative of the formation of tight junctions, and mucus production. Cells 2020, 9, 2377 3 of 13 2.3. Virus Infection The isolates SARS-CoV-2/1/Human/2020/Frankfurt (SARS-CoV-2/FFM1), SARS-CoV-2/2/Human/ 2020/Frankfurt (SARS-CoV-2/FFM2), SARS-CoV-2/6/Human/2020/Frankfurt (SARS-CoV-2/FFM6), and SARS-CoV-2/7/Human/2020/Frankfurt (SARS-CoV-2/FFM7) were isolated and cultivated in Caco2 cells as previously described [17,18]. Virus titers were determined as TCID50/mL in confluent cells in 96-well microtiter plates [19,20]. 2.4. Antiviral Assay Confluent cell cultures were infected with SARS-CoV-2 in 96-well plates at a multiplicity of infection (MOI) of 0.01 in the absence or presence of the drug. The cytopathogenic effect (CPE) was assessed visually 48 h post-infection [19]. Concentrations that inhibited CPE formation by 50% (IC50) were determined using CalcuSyn (Biosoft, Cambridge, UK). 2.5. Viability Assay Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay modified after Mosman [21], as previously described [22]. Confluent cell cultures in 96-well plates were incubated with the drug for 48 h. Then, 25 µL of MTT solution (2 mg/mL (w/v) in PBS) were added per well, and the plates were incubated at 37 ◦C for an additional 4 h. After this, the cells were lysed using 200 µL of a buffer containing 20% (w/v) sodium dodecylsulfate and 50% (v/v) N,N-dimethylformamide with the pH adjusted to 4.7 at 37 ◦C for 4 h. Absorbance was determined at 570 nm for each well using a 96-well multiscanner (Tecan, Crailsheim, Germany). After subtracting of the background absorption, the results are expressed as percentage viability relative to control cultures that received no drug. Drug concentrations that inhibited cell viability by 50% (CC50) were determined using CalcuSyn (Biosoft). 2.6. Immunostaining for SARS-CoV-2 S Protein Immunostaining was performed as previously described [23], using a monoclonal antibody directed against SARS-CoV-2 S protein (1:1500 dilution, Sino Biological, Eschborn, Germany) 24 h post-infection. 2.7. Caspase 3/7 Activation Caspase 3/7 activation was determined using the Caspase-Glo® 3/7 Assay (Promega, Walldorf, Germany) according to the manufacturer’s instructions. 2.8. qPCR SARS-CoV-2 RNA from the cell culture supernatant samples was isolated using AVL buffer and the QIAamp Viral RNA Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Absorbance-based quantification of the RNA yield was performed using the Genesys 10S UV-Vis Spectrophotometer (Thermo Fisher Scientific, Dreieich, Germany). RNA was subjected to OneStep qRT-PCR analysis using the Luna Universal One-Step RT-qPCR Kit (New England Biolabs, Frankfurt am Main, Germany) and a CFX96 Real-Time System, C1000 Touch Thermal Cycler (Bio-Rad, Feldkirchen, Germany).
Load more

Recommended publications
  • The Comparative Clinical Performance of Four SARS-Cov-2 Rapid Antigen Tests and Their Correlation to Infectivity in Vitro
    Journal of Clinical Medicine Article The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro Niko Kohmer 1,†, Tuna Toptan 1,† , Christiane Pallas 1, Onur Karaca 1, Annika Pfeiffer 1 , Sandra Westhaus 1, Marek Widera 1 , Annemarie Berger 1, Sebastian Hoehl 1 , Martin Kammel 2,3, Sandra Ciesek 1,4,5,*,‡ and Holger F. Rabenau 1,*,‡ 1 Institute for Medical Virology, University Hospital, Goethe University Frankfurt, 60596 Frankfurt, Germany; [email protected] (N.K.); [email protected] (T.T.); [email protected] (C.P.); [email protected] (O.K.); [email protected] (A.P.); [email protected] (S.W.); [email protected] (M.W.); [email protected] (A.B.); [email protected] (S.H.) 2 Institut fuer Qualitaetssicherung in der Virusdiagnostik-IQVD der GmbH, 14129 Berlin, Germany; [email protected] 3 INSTAND Gesellschaft zur Foerderung der Qualitaetssicherung in Medizinischen Laboratorien e.V., 40223 Duesseldorf, Germany 4 German Centre for Infection Research, External Partner Site, 60323 Frankfurt, Germany 5 Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine and Pharmacology, 60596 Frankfurt, Germany * Correspondence: [email protected] (S.C.); [email protected] (H.F.R.); Tel.: +49-696-301-5219 (S.C.); Tel.: +49-696-301-5312 (H.F.R.) † These authors contributed equally to this work. ‡ These authors contributed equally to this work. Abstract: Citation: Kohmer, N.; Toptan, T.; Due to globally rising numbers of severe acute respiratory syndrome coronavirus 2 (SARS- Pallas, C.; Karaca, O.; Pfeiffer, A.; CoV-2) infections, resources for real-time reverse-transcription polymerase chain reaction (rRT-PCR)- Westhaus, S.; Widera, M.; Berger, A.; based testing have been exhausted.
    [Show full text]
  • Cross-Linking of Alpha 2-Plasmin Inhibitor to Fibrin by Fibrin- Stabilizing Factor
    Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin- stabilizing factor. Y Sakata, N Aoki J Clin Invest. 1980;65(2):290-297. https://doi.org/10.1172/JCI109671. Research Article The concentration of alpha 2-plasmin inhibitor in blood plasma is higher than that in serum obtained from the blood clotted in the presence of calcium ions, but is the same as that in serum obtained in the absence of calcium ions. Radiolabeled alpha2-plasmin inhibitor was covalently bound to fibrin only when calcium ions were present at the time of clotting of plasma or fibrinogen. Whereas, when batroxobin, a snake venom enzyme that lacks the ability to activate fibrin- stabilizing factor, was used for clotting fibrinogen, the binding was not observed. When fibrin-stablizing, factor-deficient plasma was clotted, the specific binding of alpha 2-plasmin inhibitor to fibrin did not occur even in the presence of calcium ions and the concentration of alpha 2-plasmin inhibitor in serum was the same as that in plasma. Monodansyl cadaverine, a fluorescent substrate of the fibrin-stablizing factor, was incorporated into alpha 2-plasmin inhibitor by activated fibrin-stablizing factor. All these findings indicate that alpha 2-plasmin inhibitor is cross-linked to fibrin by activated fibrin-stabilizing factor when blood is clotted. Analysis of alpha 2-plasmin inhibitor-incorporated fibrin by sodium dodecyl sulfate gel electrophoresis showed that the inhibitor was mainly cross-linked to polymerized alpha-chains of cross-linked fibrin. Cross-linking of alpha 2-plasmin inhibitor to fibrin renders fibrin clot less susceptible to fibrinolysis by plasmin.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,019,993 Bal (45) Date of Patent: Feb
    USOO6O19993A United States Patent (19) 11 Patent Number: 6,019,993 Bal (45) Date of Patent: Feb. 1, 2000 54) VIRUS-INACTIVATED 2-COMPONENT 56) References Cited FIBRIN GLUE FOREIGN PATENT DOCUMENTS 75 Inventor: Frederic Bal, Vienna, Austria O 116 263 1/1986 European Pat. Off.. O 339 607 4/1989 European Pat. Off.. 73 Assignee: Omrix Biopharmaceuticals S.A., O 534 178 3/1993 European Pat. Off.. Brussels, Belgium 2 201993 1/1972 Germany. 2 102 811 2/1983 United Kingdom. 21 Appl. No.: 08/530,167 PCTUS85O1695 9/1985 WIPO. PCTCH920.0036 2/1992 WIPO. 22 PCT Filed: Mar. 27, 1994 PCT/SE92/ 00441 6/1992 WIPO. 86 PCT No.: PCT/EP94/00966 PCTEP9301797 7/1993 WIPO. S371 Date: Nov.30, 1995 Primary Examiner-Carlos Azpuru Attorney, Agent, or Firm-Jacobson, Price, Holman, & S 102(e) Date: Nov.30, 1995 Stern, PLLC 87 PCT Pub. No.: WO94/22503 57 ABSTRACT PCT Pub. Date: Oct. 13, 1994 A two-component fibrin glue for human application includes 30 Foreign Application Priority Data a) a component A containing i) a virus-inactivated and concentrated cryoprecipitate that contains fibrinogen, and ii) Mar. 30, 1993 EP European Pat. Off. .............. 93105298 traneXamic acid or a pharmaceutically acceptable Salt, 51 Int. Cl." A61F 2/06; A61K 35/14 thereof, and b) component B containing a proteolytic 52 U s C - - - - - - - - - - - - - - - - - - - - - - - - - - -424/426. 530,380, 530/381: enzyme that, upon combination with component A, cleaves, O X O -- O - - - s 530(383. 530ass Specifically, fibrinogen present in the cryoprecipitate of 58) Field of Search 424/426,530,380 component A, thereby, effecting a fibrin polymer.
    [Show full text]
  • Safety and Efficacy of Prothrombin Complex Concentrate As First-Line
    Cappabianca et al. Critical Care (2016) 20:5 DOI 10.1186/s13054-015-1172-6 RESEARCH Open Access Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery Giangiuseppe Cappabianca1†, Giovanni Mariscalco2*† , Fausto Biancari3, Daniele Maselli4, Francesca Papesso1, Marzia Cottini1, Sandro Crosta5, Simona Banescu5, Aamer B. Ahmed6 and Cesare Beghi1 Abstract Background: Bleeding after cardiac surgery requiring surgical reexploration and blood component transfusion is associated with increased morbidity and mortality. Although prothrombin complex concentrate (PCC) has been used satisfactorily in bleeding disorders, studies on its efficacy and safety after cardiopulmonary bypass are limited. Methods: Between January 2005 and December 2013, 3454 consecutive cardiac surgery patients were included in an observational study aimed at investigating the efficacy and safety of PCC as first-line coagulopathy treatment as a replacement for fresh frozen plasma (FFP). Starting in January 2012, PCC was introduced as solely first-line treatment for bleeding following cardiac surgery. Results: After one-to-one propensity score–matched analysis, 225 pairs of patients receiving PCC (median dose 1500 IU) and FFP (median dose 2 U) were included. The use of PCC was associated with significantly decreased 24-h post-operative blood loss (836 ± 1226 vs. 935 ± 583 ml, p < 0.0001). Propensity score–adjusted multivariate analysis showed that PCC was associated with significantly lower risk of red blood cell (RBC) transfusions (odds ratio [OR] 0.50; 95 % confidence interval [CI] 0.31–0.80), decreased amount of RBC units (β unstandardised coefficient −1.42, 95 % CI −2.06 to −0.77) and decreased risk of transfusion of more than 2 RBC units (OR 0.53, 95 % CI 0.38–0.73).
    [Show full text]
  • A Study on Ulinastatin in Preventing Post ERCP Pancreatitis
    International Journal of Advances in Medicine Vedamanickam R et al. Int J Adv Med. 2017 Dec;4(6):1528-1531 http://www.ijmedicine.com pISSN 2349-3925 | eISSN 2349-3933 DOI: http://dx.doi.org/10.18203/2349-3933.ijam20175083 Original Research Article A study on ulinastatin in preventing post ERCP pancreatitis R. Vedamanickam1, Vinoth Kumar2*, Hariprasad2 1Department of Medicine, 2Department of Gasto and Hepatology , SREE Balaji Medical College and Hospital, Chrompet, Chennai, Tamil Nadu, India Received: 19 September 2017 Accepted: 25 October 2017 *Correspondence: Dr. Vinothkumar, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Pancreatitis remains the major complication of endoscopic retrograde cholangiopancreatography (ERCP), and hyperenzymemia after ERCP is common. Ulinastatin, a protease inhibitor, has proved effective in the treatment of acute pancreatitis. The aim of this study was to assess the efficacy of ulinastatin, compare to placebo study to assess the incidence of complication due to ERCPP procedure. Methods: In this study a randomized placebo controlled trial, patients undergoing the first ERCP was randomizing to receive ulinastatin one lakh units (or) placebo by intravenous infusion one hour before ERCP for ten minutes duration. Clinical evaluation, serum amylase, ware analysed before the procedure 4 hours and 24 hours after the procedure. Results: Total of 46 patients were enrolled (23 in ulinastatin and 23 in placebo group).
    [Show full text]
  • Antibody-Mediated Neutralization of Authentic SARS-Cov-2 B.1.617 Variants Harboring L452R and T478K/E484Q
    viruses Communication Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q Alexander Wilhelm 1, Tuna Toptan 1 , Christiane Pallas 1, Timo Wolf 2, Udo Goetsch 3, Rene Gottschalk 3 , Maria J. G. T. Vehreschild 2,4,5, Sandra Ciesek 1,5,6,† and Marek Widera 1,*,† 1 Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; [email protected] (A.W.); [email protected] (T.T.); [email protected] (C.P.); [email protected] (S.C.) 2 Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; [email protected] (T.W.); [email protected] (M.J.G.T.V.) 3 Health Protection Authority of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany; [email protected] (U.G.); [email protected] (R.G.) 4 University Center for Infectious Diseases (UCI), University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany 5 German Center for Infection Research (DZIF), 38124 Braunschweig, Germany 6 Branch Translational Medicine and Pharmacology, Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), 60596 Frankfurt am Main, Germany * Correspondence: [email protected]; Tel.: +49-696-3018-6102; Fax: +49-69-6301-6477 † These authors equally contributed to this work. Abstract: The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) Citation: Wilhelm, A.; Toptan, T.; to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against Pallas, C.; Wolf, T.; Goetsch, U.; infections.
    [Show full text]
  • Antiproteases in Preventing Post-ERCP Acute Pancreatitis
    JOP. J Pancreas (Online) 2007; 8(4 Suppl.):509-517. ROUND TABLE Antiproteases in Preventing Post-ERCP Acute Pancreatitis Takeshi Tsujino, Takao Kawabe, Masao Omata Department of Gastroenterology, Faculty of Medicine, University of Tokyo. Tokyo, Japan Summary there is no other randomized, placebo- controlled trial on ulinastatin under way. Pancreatitis remains the most common and Large scale randomized controlled trials potentially fatal complication following revealed that both the long-term infusion of ERCP. Various pharmacological agents have gabexate and the short-term administration of been used in an attempt to prevent post-ERCP ulinastatin may reduce pancreatic injury, but pancreatitis, but most randomized controlled these studies involve patients at average risk trials have failed to demonstrate their of developing post-ERCP pancreatitis. efficacy. Antiproteases, which have been Additional research is needed to confirm the clinically used to manage acute pancreatitis, preventive efficacy of these antiproteases in would theoretically reduce pancreatic injury patients at a high risk of developing post- after ERCP because activation of proteolytic ERCP pancreatitis. enzymes is considered to play an important role in the pathogenesis of post-ERCP pancreatitis. Gabexate and ulinastatin have Introduction recently been evaluated regarding their efficacy in preventing post-ERCP ERCP is widely performed for the diagnosis pancreatitis. Long-term (12 hours) infusion of and management of various pancreaticobiliary gabexate significantly decreased the incidence diseases. Early complications after ERCP of post-ERCP pancreatitis; however, no include acute pancreatitis, bleeding, prophylactic effect was observed for short- perforation, and infection (cholangitis and term infusion (2.5 and 6.5 hours). These cholecystitis) [1, 2]. Of these ERCP-related results may be due to the short-life of complications, pancreatitis remains the most gabexate (55 seconds).
    [Show full text]
  • Alternatives and Adjuncts to Blood Transfusion
    Joint United Kingdom (UK) Blood Transfusion and Tissue PDF Generated JPAC Transplantation Services Professional Advisory Committee 02/10/2021 03:05 Transfusion Handbook Update 6: Alternatives and adjuncts to blood transfusion http://www.transfusionguidelines.org/transfusion-handbook-update/6-alternatives-and-adjuncts-to-blood-transfusion 6: Alternatives and adjuncts to blood transfusion Essentials Transfusion alternatives were mostly developed to reduce blood use in surgery but have much wider application. They are most effective when used in combination and as part of a comprehensive patient blood management programme. Predeposit autologous blood donation before surgery is of uncertain benefit and now has very restricted indications in the UK. Intraoperative cell salvage (ICS) is effective (and may be life-saving) in elective or emergency high blood loss surgery and management of major haemorrhage. Postoperative cell salvage (PCS) and reinfusion can reduce blood use in joint replacement and scoliosis surgery. ICS and PCS are usually acceptable to Jehovah’s Witnesses. Tranexamic acid (antifibrinolytic) is inexpensive, safe and reduces mortality in traumatic haemorrhage. It reduces bleeding and transfusion in many surgical procedures and may be effective in obstetric and gastrointestinal haemorrhage. Off-label use of recombinant activated Factor VII (rFVIIa) for haemorrhage does not reduce mortality and can cause serious thromboembolic complications. Erythropoiesis stimulating agents (ESAs), such as erythropoietin, are standard therapy in renal anaemia and can support blood conservation in some cancer chemotherapy patients and autologous blood donation programmes. They may also be effective in selected patients with myelodysplasia. ESAs may cause hypertension and thromboembolic problems. Careful monitoring is required to keep the haematocrit below 35%.
    [Show full text]
  • ACCEPTING CHALLENGES Photo: Peter Kiefer
    Foto: Peter Kiefer 2019 | 2020 YEARBOOK ACCEPTING CHALLENGES Photo: Peter Kiefer With over 46,000 students in the “Regulation of DNA Repair and Ge- 2019/2020 winter semester, Goethe nome Stability”. It is the first CRC to University was and is by far the largest actually involve all three Rhine-Main university in Hessen. 590 professors universities. are engaged there in teaching and re- search; 16 faculties offer a total of 130 In the framework of the “Academic degree programmes on 5 campuses. Welcome Programme for Highly Qualified Refugees (AWP)”, in In 2019, Goethe University again the 2019/2020 winter semester 46 reached a new peak in third-party refugees began preparing to study funding. With € 203.7 million including at Goethe University. Of the new LOEWE funds, it is at a very high level. participants, 24 percent are from Almost a third of the available budget Syria, 17 percent from Afghanistan, is raised competitively. 37 percent from Turkey and together 22 percent from Iran, Iraq, Pakistan, In September 2019, over 250 dele- Somalia and Azerbaijan. 40 percent gates accepted the invitation to the are women. 42 graduates successfully first“Day of the Rhine-Main Universi- completed the AWP in 2019. ties” on Westend Campus to exchange views on collaboration in teaching and research between the universities of Frankfurt, Darmstadt and Mainz. For example, 2019 saw the start of Collab- orative Research Centre (CRC 1361) Photo: Peter Kiefer With over 46,000 students in the “Regulation of DNA Repair and Ge- 2019/2020 winter semester, Goethe nome Stability”. It is the first CRC to University was and is by far the largest actually involve all three Rhine-Main university in Hessen.
    [Show full text]
  • Neuberufene Professor*Innen
    Neuberufene Professor*innen Prof. Dr. Sandra Ciesek Prof. Dr. Sandra Ciesek Fachbereich Medizin Professur für Medizinische Virologie Mehr zur Person in Fragen und Antworten Was war Ihre letzte Station vor der Goethe-Universität und was hat Sie nach Frankfurt gezogen? Bevor ich nach Frankfurt gekommen bin, war ich am Universitätsklinikum Essen an der Universität Duisburg- Essen als W2-Professorin für Virologie. Nach Frankfurt hat mich meine neue Aufgabe –die Leitung eines eigenen Instituts – gezogen. Was fasziniert Sie derzeit am meisten in der Forschung? Wir befinden uns derzeit in einer Pandemie, ausgelöst durch ein Virus. Mich fasziniert die Geschwindigkeit des Erkenntnisgewinns zu diesem neuen Virus SARS-CoV-2 und hier vor allem, wie Wissenschaftler*innen unterschiedlicher Disziplinen auf der ganzen Welt zusammenarbeiten mit dem gemeinsamen Ziel, diese Pandemie zu beenden. Welches Erlebnis oder welche Person hat Sie besonders geprägt? Besonders geprägt hat mich mein Doktorvater und ehemaliger Chef Prof. Dr. Michael Manns aus Hannover, bei dem ich 13 Jahre lang beschäftigt war. Ich habe von ihm sehr viel über Führungsstile, die Bedeutung von Wissenschaft und die Förderung vom Nachwuchs gelernt. Wenn die Corona-Pandemie überwunden ist, möchte ich … … erstmal eine lange Reise machen. CV Prof. Dr. med. Sandra Ciesek Work Address: Prof. Dr. med. Sandra Ciesek Institut für Medizinische Virologie Universitätsklinikum, Goethe Universität Frankfurt Paul-Ehrlich-Str. 40 60590 Frankfurt am Main Phone: +49 69 6301-5219 E-Mail [email protected] Academic education 2018 MHBA, FAU Nürnberg-Erlangen 2018 Certificate of Microbiology, Virology and Infection Epidemiology 2013 Certificate of Internal Medicine and Gastroenterology 2011 Venia legendi in Experimental Gastroenterology, Medical School Hannover, Germany 2005 MD, Medical School Hannover, Germany Mentor: Prof.
    [Show full text]
  • Assessment of SARS-Cov-2 Transmission on an International Flight and Among a Tourist Group
    Research Letter | Public Health Assessment of SARS-CoV-2 Transmission on an International Flight and Among a Tourist Group Sebastian Hoehl, MD; Onur Karaca; Niko Kohmer, MD; Sandra Westhaus, PhD; Jürgen Graf, MD; Udo Goetsch, MD; Sandra Ciesek, MD Introduction This case series assessed a commercial airline flight from Tel Aviv, Israel, to Frankfurt, Germany, that Author affiliations and article information are occurred on March 9th, 2020. Among 102 passengers on a Boeing 737-900 aircraft were 24 listed at the end of this article. members of a tourist group. Starting 7 days earlier, the group had contact with a hotel manager who later received a diagnosis of coronavirus disease 2019 (COVID-19). No member of the group had received a diagnosis of COVID-19 before the flight, and no measures to prevent transmission (eg, wearing of masks) had been applied. The flight duration was 4 hours 40 minutes. Methods At the destination airport, we conducted a medical evaluation of the tourist group, including testing for severe acute respiratory syndrome coronavirus (SARS-CoV-2) in a throat swab specimen. In addition, we contacted all passengers 4 to 5 weeks later by phone and conducted structured interviews. Passengers were asked whether they had contact with a person with COVID-19. They were prompted to report symptoms and asked about previous testing for SARS-CoV-2. A semiquantitative SARS-CoV-2 IgG antibody test (EUROIMMUN) was offered to all passengers who had been seated within 2 rows of the index cases and to those who reported to have been symptomatic. Borderline and positive results in the IgG test were confirmed with a plaque reduction neutralization test (PRNT).
    [Show full text]
  • Prothrombin Complex Concentrates: a Brief Review
    European Journal of Anaesthesiology 2008; 25: 784–789 r 2008 Copyright European Society of Anaesthesiology doi:10.1017/S0265021508004675 Review Prothrombin complex concentrates: a brief review C. M. Samama Hotel-Dieu University Hospital, Department of Anaesthesiology and Intensive Care, Paris Cedex, France Summary Prothrombin complex concentrates are haemostatic blood products containing four vitamin K-dependent clotting factors (II, VII, IX and X). They are a useful, reliable and fast alternative to fresh frozen plasma for the reversal of the effects of oral anticoagulant treatments (vitamin K antagonists). They are sometimes used for factor II or factor X replacement in patients with congenital or acquired deficiencies. They are widely prescribed in Europe. Several retrospective and prospective studies have demonstrated their efficacy in nor- malizing coagulation and in helping to control life-threatening bleeding. Few side-effects, mainly throm- boembolic events, have been reported. The link between these events and prothrombin complex concentrate infusion has, however, often been brought into question. The use of prothrombin complex concentrates in new promising indications such as the management of massive bleeding requires prospective studies providing a high level of evidence in a high-risk setting. Keywords: PROTHROMBIN COMPLEX CONTENTRATES; VITAMIN K; HAEMORRHAGE; DISSEMINATED INTRAVASCULAR COAGULATION; BLEEDING; THROMBOSIS; FACTOR IX. Introduction and side-effects, and on suggested extensions to their current authorized indications. It will not address Prothrombin complex concentrates (PCCs) are highly activated PCCs for the treatment of patients having purified concentrates with haemostatic activity pre- clotting factor inhibitors. pared from pooled plasma. They contain four vitamin K-dependent clotting factors (F) (II (prothrombin), VII, IX and X).
    [Show full text]